Solid Tumors: Dose Escalation Only (Disease-Specific Expansion)

- **Solid tumors with PTEN or PIK3CB mutations**
  - Expansion: breast, prostate, other solid tumors
  - ▼ 10131: Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel

- **Solid tumors, no specific mutations**
  - Expansion: at least one pancreatic cancer cohort and possibly others
  - 10244: Phase I Study of GSK525762 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
  - Expansion: recurrent small cell lung cancer
  - ▼ 10070: Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients with Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
  - Expansion: recurrent epithelial ovarian, fallopian tube, peritoneal cancer or recurrent TNBC
  - ▼ 10031: A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
  - Phase 2: advanced cholangiocarcinoma/ gallbladder carcinoma
  - * 10276: A Phase II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: August 23, 2019